IBRX

Over the past six months (March 2026 - September 2026), ImmunityBio's stock (IBRX) has been impacted by several key events. In March 2026, the European Commission granted conditional marketing authorization for ANKTIVA, and the company expanded its presence into Saudi Arabia through partnerships, leading to investor optimism and an increase in the stock price following promising clinical trial results. In May 2026, several class-action lawsuits were filed against ImmunityBio, which could have created negative sentiment among investors. In July 2026, ImmunityBio received Marketing Authorization from the Emirates Drug Establishment in the UAE for ANKTIVA across two indications: BCG-unresponsive NMIBC and metastatic non-small cell lung cancer, expanding ANKTIVA's global regulatory footprint to 34 countries. In August 2026, the company reported record Q2 2026 net product revenue of $50.7 million, marking a 92% year-over-year increase, and Dr. Jim Yong Kim, former World Bank President, was appointed as Vice Chairman. In September 2026, the FDA accepted a supplemental Biologics License Application (BLA) for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease, with a Prescription Drug User Fee Act (PDUFA) target date of January 6, 2027. ImmunityBio also secured exclusive U.S. rights for Tokyo-172 BCG. The stock saw a 7% surge after its founder led an $11.3 million PIPE financing for PDS Biotechnology, which renewed investor focus on potential pipeline synergies. There was also speculation among retail traders about IBRX potentially becoming a tokenized stock following a tease from the founder regarding blockchain-based stock trading. Overall, the stock has experienced significant gains over the past year and year-to-date.